Motor Neuron Disease
96
21
24
45
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
8 terminated out of 96 trials
84.9%
-1.6% vs benchmark
3%
3 trials in Phase 3/4
16%
7 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 45 completed trials
Clinical Trials (96)
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Study of Inherited Neurological Disorders
Functional Outcomes and Control Using Synchron BCI - Australia
Virtual Peer-to-peer Support Programme for Carers of MND
Genetic Diagnosis in Inborn Errors of Metabolism
Telehealth in Motor Neurone Disease
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
Study of Predictive Factors of Progression of Motor Neurone Disease
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Non-invasive BCI-controlled Assistive Devices
Functional Outcomes and Control Using Synchron BCI - Canada
Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Digital App for Speech & Health Monitoring
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families